Graphene-Enhanced Healthcare Solutions

ZEN’s patent-pending graphene-based biocidal coating has 99%+ proven effectiveness against viruses, fungi and bacteria.

We are working with TreborRx and other partners globally to bring this much needed innovation forward to better protect our healthcare workers and the public. With the requisite Health Canada approvals and safety data in place, ZEN coated masks are now a commercial reality. Given the effectiveness and versatility of our coating, we have an agreement in place to coat nitrile gloves and are exploring other applications that can bring an added layer of protection to the healthcare and other industries globally.

Broad-Spectrum Effectiveness

With 99.9% effectiveness against bacteria, fungi and viruses, the ability to achieve those levels with an extremely low minimum inhibitory concentration (MIC) and excellent safety results, ZEN’s patent-pending graphene-based formulation is a potential game changer for treating human-contracted pathogens and infectious disease management.

ZEN Graphene Solutions Develops Novel Graphene-Based Potential Treatment for Bacterial and Viral Infections in Humans

Antimicrobial Resistance (AMR) – Fighting A Global Threat

The World Health Organization lists AMR as a top 10 global public health threat facing humanity, largely due to the misuse and overuse of antimicrobials. With significant human impact and additional global healthcare expenditures expected to reach US$1.2 trillion annually by 2050 due to AMR, it is clear why the WHO, numerous AMR-focused organizations, and some of the world’s largest and most innovative companies are allocating substantial resources to this cause. To address this global threat, we believe novel, broad-spectrum and antimicrobial agents are needed, and we are demonstrating that nanotechnology and our graphene-based compound can potentially play a key role. Recent results have shown our patent-pending graphene-based compound is effective against four gram-positive and nine gram-negative bacteria with antimicrobial-resistance, including multidrug-resistant variants like methicillin-resistant staphylococcus aureus (MRSA).

We are consulting with multiple groups and regulatory agencies on how to fast track this technology given it’s potential to help address the growing global threat of antimicrobial resistance and the SARS-CoV-2 virus and its variants.